3-对甲苯-1H-吡唑-5-羧酸甲酯 | 192701-73-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-对甲苯-1H-吡唑-5-羧酸甲酯
• 英文名称: methyl 3-(p-tolyl)-1H-pyrazole-5-carboxylate
• 英文别名: methyl 3-(4-methylphenyl)-1H-pyrazole-5-carboxylate
• CAS: 192701-73-8
• 化学式: C₁₂H₁₂N₂O₂
• mdl: MFCD03778978
• 分子量: 216.239
• InChiKey: QQBASWCUEOBWNQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  55
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933199090
• WGK Germany：
  3
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : Methyl 3-P-Tolyl-1H-Pyrazole-5-Carboxylate
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
This substance is not classified as dangerous according to Directive 67/548/EEC.
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 216,24 g/mol
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Avoid
breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  3-对甲苯-1H-吡唑-5-羧酸甲酯 在 4-二甲氨基吡啶 、 lithium hydroxide monohydrate 、 potassium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 10.0h， 生成 1-benzyl-3-(4-methylphenyl)-N'-quinolin-2-yl-1H-pyrazole-5-carbohydrazide
  参考文献：
  名称：

  新型吡唑-3（5）-羧酸衍生物的镇痛，抗炎和抗癌活性的合成和评价

  摘要：

  在本文中，我们合成了一系列新型的1-苄基-5（3）-对甲苯基-1 H-吡唑-3（5）-羧酸衍生物，并通过IR，1 H NMR和质谱进行了表征。分别使用对苯醌诱导的扭体试验和角叉菜胶诱导的爪水肿模型评估化合物的体内止痛和抗炎活性。在测试的14种化合物中，7a，7c，7e，7f，7i，8a – b和8f – g与参比药物阿司匹林和消炎痛相比，具有较强的止痛和/或消炎作用。使用MTT分析评估了这些化合物对五种癌细胞系的抗癌活性（HL-60，人类早幼粒细胞白血病细胞； HeLa，人类宫颈癌细胞； Raji，人类B淋巴细胞细胞系； MCF7，人类乳腺癌细胞； MDA） -MB-231，非雌激素依赖性人乳腺癌细胞系）。具有高抗炎活性的化合物7a，8a和8b以及具有轻度抗炎活性的7d和7j也显示出对某些所选细胞系的有希望的抗癌活性。

  DOI：

  10.1007/s00044-012-0072-4
• 作为产物：
  描述：

  4-(4-甲基苯基)-2,4-二氧代丁酸甲酯 在 一水合肼 、 溶剂黄146 作用下， 反应 1.0h， 生成 3-对甲苯-1H-吡唑-5-羧酸甲酯
  参考文献：
  名称：

  杂芳族连接的4β-酰胺基鬼臼毒素作为细胞凋亡诱导剂的合成及抗癌活性

  摘要：

  合成了一系列不同的杂芳族连接的4β-酰胺基鬼臼毒素偶联物（16a – i，17a – i和18a – d），并评估了其对五种人类癌细胞系的抗癌活性。在该系列中，一种化合物17g在A549（肺癌）细胞系中显示出显着的抗增殖活性。流式细胞仪分析表明，17g细胞在G2 / M期停滞，导致caspase-3依赖性凋亡细胞死亡。此外，Hoechst 33258染色和DNA片段化分析还表明17g通过凋亡诱导细胞死亡。

  DOI：

  10.1016/j.bmcl.2012.10.099

文献信息

• Synthesis and anticancer activity of heteroaromatic linked 4β-amido podophyllotoxins as apoptotic inducing agents
  作者：Ahmed Kamal、Jaki R. Tamboli、M.V.P.S. Vishnuvardhan、S.F. Adil、V. Lakshma Nayak、S. Ramakrishna

  DOI：10.1016/j.bmcl.2012.10.099

  日期：2013.1

  17a–i and 18a–d) were synthesized and evaluated for anticancer activity against five human cancer cell lines. Among the series, one of the compound 17g showed significant antiproliferative activity in A549 (lung cancer) cell line. Flow cytometric analysis showed that 17g arrested the cell cycle in the G2/M phase leading to caspase-3 dependent apoptotic cell death. Further, Hoechst 33258 staining and DNA

  合成了一系列不同的杂芳族连接的4β-酰胺基鬼臼毒素偶联物（16a – i，17a – i和18a – d），并评估了其对五种人类癌细胞系的抗癌活性。在该系列中，一种化合物17g在A549（肺癌）细胞系中显示出显着的抗增殖活性。流式细胞仪分析表明，17g细胞在G2 / M期停滞，导致caspase-3依赖性凋亡细胞死亡。此外，Hoechst 33258染色和DNA片段化分析还表明17g通过凋亡诱导细胞死亡。
• Intramolecular Cyclization of Vinyldiazoacetates as a Versatile Route to Substituted Pyrazoles
  作者：Ivan Vilotijevic、Denis Drikermann、Valerie Kerndl、Helmar Görls

  DOI：10.1055/s-0040-1707111

  日期：2020.7

  Vinyldiazo compounds undergo a thermal electrocyclization to form pyrazoles in yields of up to 95%. The reactions are operationally simple, use readily available starting materials, require no intervention of a catalyst, and enable the synthesis of mono-, di- and tri-substituted pyrazoles. With the ability to produce highly substituted pyrazoles and the flexibility in installing various types of substituents

  乙烯基重氮化合物经过热电环化形成吡唑，产率高达 95%。该反应操作简单，使用容易获得的原料，不需要催化剂的干预，并且能够合成单、二和三取代的吡唑。由于能够生产高度取代的吡唑，并且可以灵活地安装各种类型的取代基，这种方法构成了这种有价值的杂环支架的新入口，可能对化学工业的所有分支感兴趣。
• N-(METHYL) -1H-PYRAZOL-3-AMINE, N-(METHYL)-PYRIDIN-2-AMINE AND N-(METHYL)-THIAZOL-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S
  申请人：Froestl Wolfgang

  公开号：US20100183513A1

  公开（公告）日：2010-07-22

  The present invention relates to novel compounds of formula (II) that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating, or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.

  本发明涉及式（II）的新化合物，可用于治疗与淀粉样蛋白相关的一组紊乱和异常，如阿尔茨海默病，以及与淀粉样蛋白类似的蛋白质相关的疾病或病况。本发明的化合物还可用于治疗与视觉系统组织的病理性异常/变化相关的眼部疾病。本发明还涉及包含这些化合物的制药组合物，并且涉及使用这些化合物制备用于治疗或预防与淀粉样和/或淀粉样类似蛋白质相关的疾病或病况的药物。还公开了一种治疗或预防与淀粉样和/或淀粉样类似蛋白质相关的疾病或病况的方法。
• NOVEL COMPOUND FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS
  申请人：FROESTL Wolfgang

  公开号：US20120309791A1

  公开（公告）日：2012-12-06

  The present invention relates to novel compounds of formula (II) that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating, or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed

  本发明涉及公式（II）的新化合物，可用于治疗与淀粉样蛋白相关的一组疾病和异常，例如阿尔茨海默病，以及与淀粉样蛋白类似蛋白质相关的疾病或病况。本发明的化合物还可用于治疗与视觉系统组织病理异常/变化相关的眼部疾病。本发明还涉及包含这些化合物的制药组合物以及使用这些化合物制备治疗或预防与淀粉样和/或淀粉样类似蛋白质相关的疾病或病况的药物的用途。还公开了一种治疗或预防与淀粉样和/或淀粉样类似蛋白质相关的疾病或病况的方法。
• Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
  申请人：Froestl Wolfgang

  公开号：US08673940B2

  公开（公告）日：2014-03-18

  The present invention relates to novel compounds of formula (II) that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating, or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.

  本发明涉及式（II）的新化合物，可用于治疗与淀粉样蛋白相关的一组疾病和异常，如阿尔茨海默病，以及与淀粉样蛋白类似蛋白质相关的疾病或病况。本发明的化合物还可用于治疗与视觉系统组织中的病理异常/变化相关的眼部疾病。本发明还涉及包含这些化合物的制药组合物，并且涉及使用这些化合物制备用于治疗或预防与淀粉样和/或淀粉样类似蛋白质相关的疾病或病况的药物。还公开了一种治疗或预防与淀粉样和/或淀粉样类似蛋白质相关的疾病或病况的方法。